Working out of a tribal-owned hospital in Anchorage, Alaska, liver specialist Brian McMahon has spent decades treating the long shadow of hepatitis B. Before a vaccine became available in the 1980s, he saw the virus claim young lives in western Alaskan communities with stunning speed. One of his patients was 17 years old when he…
You don’t have to practice in Florida for this law to matter. Patient interest in regenerative care is growing rapidly, and physicians across the country need to be prepared to understand and consider advising patients, where applicable, of these stem cell-related treatment options. The post Florida’s New Stem Cell Law: What It Signals for Physicians,…
In partnership with Cost Plus Drugs and Waltz Health, Serve You Rx has added Stelara biosimilars Otulfi and Yesintek to its formulary. The post Serve You Rx Adds 2 Stelara Biosimilars to Formulary to Help Patients Save Costs appeared first on MedCity News.
By integrating AI with human oversight, Reimagine Care aims to enhance virtual oncology care
Proposals from some Republicans in Congress would effectively repeal some or all of the ACA premium tax credits and replace them with contributions to Health Savings Accounts (HSAs) or something similar. Senator Rick Scott proposes “Trump Health Freedom Accounts” and Senator Bill Cassidy proposes HSA contributions available only for people who enroll in bronze level…
Impact of ‘One Big Beautiful Bill’ on rural hospital financesBrain implant lets patient with ALS speak and singImpact of children’s disability on parent’s mental health.COVID is back?How does this man defy aging?
GSK is licensing an ABL Bio technology yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease. The post GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier…
Boehringer-Ingelheim pill Hernexeos was awarded accelerated FDA approval for advanced cases of non-small cell lung cancer with HER2 mutations. But Bayer is on its heels with an oral small molecule currently under FDA review in the same indication. The post FDA Nod Makes Boehringer Ingelheim Drug an Alternative to AstraZeneca ADC in Lung Cancer appeared…
As the field of oncology evolves, we need to shift away from traditional binary “yes-no” biomarkers to a more nuanced, spatial understanding of tumor biology. This approach will allow for more personalized treatment plans that are tailored to the unique characteristics of each patient’s tumor. The post Targeting the Blast Radius: Why Spatial AI Diagnostics…
In mid-May, Mandi Rokx had a 3-month-old baby and a letter from a Florida agency warning that they both would be cut from Medicaid, the health insurance program for people with low incomes or disabilities. Under a Florida law passed in 2021, Rokx was supposed to receive 12 months of continuous coverage after giving birth….